There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT), Atossa Genetics (ATOS) and Titan Medical Inc (TMDI) with bullish sentiments.
Sarepta Therapeutics (SRPT)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics today and set a price target of $267. The company’s shares closed yesterday at $118.68.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.1% and a 47.2% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $207.94 average price target, which is a 75.2% upside from current levels. In a report issued on March 25, Needham also maintained a Buy rating on the stock with a $196 price target.
See today’s analyst top recommended stocks >>
Atossa Genetics (ATOS)
In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Atossa Genetics, with a price target of $9. The company’s shares closed yesterday at $3.70.
McCarthy observed:
“Atossa reported FYE18 with a net loss of ($11.4M). Although the company ended the period with $10.5M in cash on the balance sheet, it received an additional $11.3M from the exercise of warrants in 1Q19. We estimate that the company currently has ~$19M in cash and sufficient runway into 2020.”
According to TipRanks.com, McCarthy has currently no stars on a ranking scale of 0-5 stars, with an average return of -8.3% and a 29.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.
Currently, the analyst consensus on Atossa Genetics is a Moderate Buy with an average price target of $9.
Titan Medical Inc (TMDI)
In a report released today, Anthony Vendetti from Maxim Group maintained a Buy rating on Titan Medical Inc, with a price target of $5. The company’s shares closed yesterday at $3.
Vendetti wrote:
“Market close, TMDI held a business update call on its 4Q18 results and the development of its SPORT Surgical System. 2019, TMDI closed its public offering of 7,352,941 units at $3.40 per unit for gross proceeds of approximately $25M. As a result, we are lowering our price target to $5, from $8, on greater share dilution from the equity raise. See Figure 1: TMDI a timeline of the SPORT Surgical System.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 6.1% and a 52.6% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Ra Medical Systems Inc.
Currently, the analyst consensus on Titan Medical Inc is a Moderate Buy with an average price target of $7.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
